EMERGENT BIOSOLUTIONS INC (EBS) Stock Price, Forecast & Analysis
USA • New York Stock Exchange • NYSE:EBS • US29089Q1058
EBS Key Statistics, Chart & Performance
The current stock price of EBS is 10.92 USD. In the past month the price decreased by -18.26%. In the past year, price increased by 9.2%.
EBS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to EBS. When comparing the yearly performance of all stocks, EBS turns out to be only a medium performer in the overall market: it outperformed 60.61% of all stocks.
EBS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EBS. EBS has an average financial health and profitability rating.
EBS Financial Highlights
Over the last trailing twelve months EBS reported a non-GAAP Earnings per Share(EPS) of 1.98. The EPS increased by 275.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.62% | ||
| ROA | 5.2% | ||
| ROE | 13.03% | ||
| Debt/Equity | 1.14 |
EBS Forecast & Estimates
6 analysts have analysed EBS and the average price target is 13.77 USD. This implies a price increase of 26.1% is expected in the next year compared to the current price of 10.92.
For the next year, analysts expect an EPS growth of 767.9% and a revenue growth -26.68% for EBS
EBS Ownership
EBS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EBS
Company Profile
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 900 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Company Info
EMERGENT BIOSOLUTIONS INC
300 Professional Dr
Gaithersburg MARYLAND 20879 US
CEO: Robert G. Kramer
Employees: 900
Phone: 12406313200
EMERGENT BIOSOLUTIONS INC / EBS FAQ
Can you describe the business of EMERGENT BIOSOLUTIONS INC?
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 900 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Can you provide the latest stock price for EMERGENT BIOSOLUTIONS INC?
The current stock price of EBS is 10.92 USD. The price increased by 3.61% in the last trading session.
Does EBS stock pay dividends?
EBS does not pay a dividend.
What is the ChartMill technical and fundamental rating of EBS stock?
EBS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the employee count for EBS stock?
EMERGENT BIOSOLUTIONS INC (EBS) currently has 900 employees.
Can you provide the market cap for EMERGENT BIOSOLUTIONS INC?
EMERGENT BIOSOLUTIONS INC (EBS) has a market capitalization of 573.52M USD. This makes EBS a Small Cap stock.